Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 1
1(50.0%)
Phase 2
1(50.0%)
2Total
Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05098210Phase 1Recruiting

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Role: collaborator

NCT05889260Completed

Speech Accessibility Project

Role: collaborator

NCT04359810Phase 2Completed

Plasma Therapy of COVID-19 in Severely Ill Patients

Role: collaborator

NCT04854421Completed

Evaluation of the Accuracy of a Computer Vision-based Tool for Assessment of Total Body Fat Percentage

Role: collaborator

All 4 trials loaded